Innovation breakthrough in the Alzheimer’s disease pharmaceutical industry

Alzheimer’s disease (AD) drug development has undergone cycles, driven initially by amyloid-β–based hypotheses and later setbacks by clinical failures. Recent advances in biotechnology, improved understanding of AD pathogenesis, and unmet medical needs have revitalized the field. This new wave is exemplified by lecanemab, the first fully FDA-approved disease-modifying therapy in two decades. We review approved and clinical-stage AD therapeutics using data from Cortellis and the FDA.